Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis
We propose to study the benefits and risks of Autologous Haematopoetic Stem Cell Transplant (AHSCT) in people who have an aggressive form of MS not controlled by conventional treatment. Participants will have AHSCT at The Alfred hospital, and they will be closely monitored for 5 years post the transplant to ensure their safety, and also […]
A Phase II observational study of Haematopoietic Stem Cell Transplantation for highly active, treatment resistant MS
This trial is testing whether an autologous (self) haematopoietic stem cell transplant (AHSCT) for highly active, treatment resistant multiple sclerosis reduces MS disease activity over 5 years. The treatment involves: treatment, collection and freezing of stem cells from the patient’s blood; chemotherapy (BEAM-ATG) to destroy the immune system; reinfusion of the patient’s own stem cells. […]
Australian MS Longitudinal Study
The Australian MS Longitudinal Study (AMSLS) is not a clinical trial. It is a survey-based study of life issues, designed to more fully understand the impact of MS, including the individual and overall community impacts. The data from the AMSLS provides a regularly updated, evidence base for a number of stakeholders including health professionals, scientific […]